tirzepatide microdosing study on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Tirzepatide Microdosing: What Research Shows

patients switched to placebo regained approximately 14.0% (Aronne et al., JAMA 2024

Approach GLP-1 probiotic claims with appropriate skepticism, prioritizing evidence-based interventions for metabolic health management

Offering a weekly injection, it has the benefit of an established track record, with weight loss being an effective side effect for many diabetes patients

The dose is gradually increased over the first 16 weeks to minimise potential side effects

2011a;306(18):200110

Contact Simply Direct Medicine today to schedule your consultation and see how fast you can start achieving your goals with a tailored Semaglutide program